Rabbit anti-PGC-1 IHC Antibody, Affinity Purified IHC-00029 from Bethyl Laboratories, Inc. | Biocompare.com

Be the first to write a review!

Citations:

Supplier Page from
Bethyl Laboratories, Inc. for
Rabbit anti-PGC-1 IHC Antibody, Affinity Purified

The Rabbit anti-PGC-1 IHC Antibody, Affinity Purified from Bethyl Laboratories, Inc. is a Rabbit Polyclonal antibody to PPARGC1A. This antibody recognizes Homo Sapiens, and Human antigen. The Rabbit anti-PGC-1 IHC Antibody, Affinity Purified has been validated for the following applications: Immunohistochemistry.

Description

The epitope recognized by IHC-00029 maps to a region between residue 250 and 300 of human peroxisome proliferative activated receptor, gamma, coactivator 1, alpha using the numbering given in SwissProt entry Q9UBK2 (GeneID 10891)

Product Specs
ItemRabbit anti-PGC-1 IHC Antibody, Affinity Purified
CompanyBethyl Laboratories, Inc.
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberIHC-00029
Quantity25 µg
ApplicationsIHC
Conjugate/TagUnconjugated
FormatWhole IgG
ReactivityHuman
TargetPGC-1
HostRabbit
Antibody TypePrimary
NCBI Full Gene NamePPARG coactivator 1 alpha
NCBI Gene AliasesPGC-1alpha, PGC1, PPARGC1, PGC1A, PGC-1v, LEM6, PGC-1(alpha)
ClonalityPolyclonal
IsotypeWhole IgG
Concentration250 µg/ml
Domain/Region/TerminusBetween 250 and 300
Storage2 - 8°C

Add to Compare List

Bethyl Laboratories, Inc.

Bethyl Laboratories, Inc.

P.O. Box 850

Montgomery, Texas 77356

United States

Phone: 1-800-338-9579
Fax: 1-866-597-6105

Email: orders@fortislife.com

Company Profile

Website: fortislife.com

(1) NF-κB; the Critical Link between Immune and Metabolic Pathways: Could NF-κB be Used as a Novel Diagnostic and Prognostic Biomarker for Non-Alcoholic Steatohepatitis?OBM Hepatology and GastroenterologyJanuary 28, 2019Athina Chasapi et al.p65 ,F-6, Santa Cruz Biotechnology, USA) and rabbit polyclonal antibody against PCG-1 (1:50 dilution, IHC-00029, BETHYL Laboratories, TX, USA). Briefly, we adhered to the commonly used immunohistochemistry protocol:

(2) Alteration of energy metabolism in the pathogenesis of bile duct lesions in primary biliary cirrhosisJournal of clinical pathologyMay 1, 2014Kenichi Harada, Yuko Kakuda, Yasunori Sato, Hiroko Ikeda, Shinji Shimoda, Yasuhiko Yamamoto, Hiroshi Inoue, Hajime Ohta, Satomi Kasashima, Atsuhiro Kawashima, Yasuni Nakanuma

Be the First to Write a Review!